Our scientists and physicians conduct extensive laboratory and clinical research to identify new treatments and improve therapies for children with hematologic malignancies. Our team’s achievements include:
We lead an internationally recognized clinical trials consortium for children and adolescents with newly diagnosed acute lymphoblastic leukemia – the DFCI/ALL Consortium – consisting of 9 institutions in the United States and Canada. We are a founding member of a small national consortium of leading medical centers that investigate new treatments for children with Hodgkin lymphoma, including innovative drug combinations (and reduced exposure to radiation) that deliver results with fewer long-term complications. In addition, we participate in clinical trials conducted by the Histiocyte Society for patients with Langerhans cell histiocytosis.
To inquire about clinical trials, email us at email@example.com and read our clinical trial FAQs for answers to general questions.
in Combination With Everolimus and Dexamethasone in Relapsed ALL
This research study is a Phase I clinical trial evaluating a
drug called ribociclib (LEE011) given in combination with everolimus and other
standard of care chemotherapy
drugs as a possible treatment for relapsed
or refractory acute lymphoblastic leukemia (ALL). PI: Andrew
E. Place, MD, PhD
Phone: 617-632-5508Online form: Request an appointment
Stay informed about our clinical trials research efforts. Sign up for our email newsletter, Advances in Pediatric Hematology/Oncology.